Trypanosoma cruzi dormancy and its implications for therapeutic treatment
Trypanosoma cruzi dormancy and its implications for therapeutic treatment
批准号:
10368984
负责人:
Rick L Tarleton
金额:
$47.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-10 至 2025-02-28
关键词:
AcuteAdverse effectsAnimal OrganAnimalsAntibiotic TherapyAntiparasitic AgentsBenznidazoleBiological ProcessBiologyChagas DiseaseCharacteristicsChronicComplexDetectionDevelopmentDrug resistanceDrug usageExposure toFrequenciesGoalsHeart DiseasesHumanImageImmuneImmune responseImmune systemImmunologicsImmunotherapyIn VitroIndividualInfectionInsectaInvestigationLeadLifeLightLinkLocationMetabolicMicroscopyMolecularMonitorOutcomeParasitesPathway interactionsPatternPharmaceutical PreparationsPharmacotherapyPhenotypePlayProcessPropertyRegimenReportingResearchResistanceRiskRoleSystemTherapeuticTissuesTreatment EfficacyTreatment FailureTreatment ProtocolsTreatment outcomeTrypanocidal AgentsTrypanosoma cruziWorkacute infectionchronic infectioncytotoxicdesigndrug discoverydrug efficacyeffective therapyenvironmental stressorexperimental studyimprovedin vivomicrobialnovelnovel therapeuticspreventsmall moleculetherapeutic candidatetherapy designtool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Microbial dormancy, defined as a state of reduced metabolic activity, is well recognized in bacterial systems as a
mechanism of transient resistance to environmental stresses, including antibiotic treatment. We have recently reported
that Trypanosoma cruzi, the agent of Chagas disease, resists long-term exposure to highly cytotoxic compounds due to
the ability of a subpopulation of intracelllular amastigotes to spontaneously assume a dormant state. This new
understanding of T. cruzi biology has implications for how currently available drugs are delivered and how new
compounds capable of reversing dormancy, may be identified. In this application, we propose experiments that will
define the timeframe and limits of T. cruzi dormancy in vivo, among different parasite isolates, if different host tissues
and with respect to the chronicity of the infections. The immunological implications of dormancy will be investigated
and this parasitological and immunological information will be integrated to enhance treatment efficacy using currently
available drugs. Using a novel high content imaging screen, we will identify small molecules that prevent or reverse
dormancy and/or drive the stage conversion of both dormant and actively replicating amastigotes into trypomastigotes.
These compounds will serve as research tools to investigate the molecular pathways involved in dormancy and will be
preliminarily investigated as new therapeutic entities for Chagas disease. We believe that the observation of dormancy
in T. cruzi and the demonstration of its clear role in drug treatment failure is a game changer for treatment design and
drug discovery in T. cruzi. The work in this proposal charts a way forward for therapy for Chagas disease, using new
tools to increase our understanding of the complex set of interacting forces that determine treatment outcomes, and
integrating this information to better use current drugs and discover of new ones.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The activation of benzoxaborole prodrug AN15368, a clinical candidate for Chagas disease
-
批准号:10667721
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2023
-
负责人:Rick L Tarleton
-
依托单位:
Optimizing blood PCR as test of cure in Chagas disease
-
批准号:10451977
-
项目类别:
-
资助金额:$7.55万
-
财政年份:2022
-
负责人:Rick L Tarleton
-
依托单位:
Optimizing blood PCR as test of cure in Chagas disease
-
批准号:10590740
-
项目类别:
-
资助金额:$7.55万
-
财政年份:2022
-
负责人:Rick L Tarleton
-
依托单位:
Trypanosoma cruzi dormancy and its implications for therapeutic treatment
-
批准号:10573204
-
项目类别:
-
资助金额:$47.7万
-
财政年份:2020
-
负责人:Rick L Tarleton
-
依托单位:
Purchase of an imaging flow cytometer 2016
-
批准号:9273704
-
项目类别:
-
资助金额:$45.38万
-
财政年份:2017
-
负责人:Rick L Tarleton
-
依托单位:
Mechanisms of persistence in Trypanosoma cruzi infection
-
批准号:9754759
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2016
-
负责人:Rick L Tarleton
-
依托单位:
Multiplex treatment outcomes test for Chagas disease
-
批准号:9305839
-
项目类别:
-
资助金额:$100.08万
-
财政年份:2016
-
负责人:Rick L Tarleton
-
依托单位:
Mechanisms of persistence in Trypanosoma cruzi infection
-
批准号:9237877
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2016
-
负责人:Rick L Tarleton
-
依托单位:
Mechanisms of persistence in Trypanosoma cruzi infection
-
批准号:9979735
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2016
-
负责人:Rick L Tarleton
-
依托单位:
Generation of reference genomes for Trypanosoma cruzi using PacBio sequencing
-
批准号:9251753
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2016
-
负责人:Rick L Tarleton
-
依托单位:
Development of CRISPR/Cas system for study of trans-sialidase family genes in T. cruzi
-
批准号:9054467
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2016
-
负责人:Rick L Tarleton
-
依托单位:
Making benznidazole a better drug for Chagas disease
-
批准号:8652132
-
项目类别:
-
资助金额:$18.64万
-
财政年份:2014
-
负责人:Rick L Tarleton
-
依托单位:
Making benznidazole a better drug for Chagas disease
-
批准号:8903699
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:Rick L Tarleton
-
依托单位:
Transmission-blocking live vaccine for Chagas disease
-
批准号:8968183
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2011
-
负责人:Rick L Tarleton
-
依托单位:
Transmission-blocking live vaccine for Chagas disease
-
批准号:8585810
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2011
-
负责人:Rick L Tarleton
-
依托单位:
Transmission-blocking live vaccine for Chagas disease
-
批准号:8390470
-
项目类别:
-
资助金额:$34.9万
-
财政年份:2011
-
负责人:Rick L Tarleton
-
依托单位:
Transmission-blocking live vaccine for Chagas disease
-
批准号:8237761
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2011
-
负责人:Rick L Tarleton
-
依托单位:
Multi-color Flow Analyzer for the UGA-CTEGD Flow Facility
-
批准号:7794363
-
项目类别:
-
资助金额:$34.79万
-
财政年份:2010
-
负责人:Rick L Tarleton
-
依托单位:
Multiplex serodiagnostic test for Chagas disease
-
批准号:8103493
-
项目类别:
-
资助金额:$78.25万
-
财政年份:2010
-
负责人:Rick L Tarleton
-
依托单位:
Drug Discovery Consortium for Chagas Disease
-
批准号:7656093
-
项目类别:
-
资助金额:$113.77万
-
财政年份:2009
-
负责人:Rick L Tarleton
-
依托单位:
海外基金